NovaBay Pharmaceuticals, Inc.
NBY
$0.58
-$0.02-3.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -1.90% | -32.25% | 12.52% | 2.34% | -35.25% |
| Total Other Revenue | 70.00% | 18.18% | 0.00% | -8.33% | 0.00% |
| Total Revenue | -1.61% | -32.09% | 12.48% | 2.31% | -35.15% |
| Cost of Revenue | 3.54% | -54.99% | 13.26% | 1.27% | -43.56% |
| Gross Profit | -4.15% | -8.45% | 12.13% | 3.42% | -30.02% |
| SG&A Expenses | 12.48% | -4.77% | 14.00% | -40.41% | -15.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 10.16% | -24.69% | 14.06% | -28.54% | -25.78% |
| Operating Income | -52.01% | -0.19% | -16.80% | 70.32% | -52.74% |
| Income Before Tax | 10.42% | 8.28% | -129.74% | 49.94% | -894.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 10.42% | 8.28% | -129.74% | 49.94% | -894.85% |
| Earnings from Discontinued Operations | -- | -- | 68.53% | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.02% | 22.15% | -84.82% | 49.94% | -1,191.91% |
| EBIT | -52.01% | -0.19% | -16.80% | 70.32% | -52.74% |
| EBITDA | -53.58% | -0.39% | -17.04% | 70.85% | -102.66% |
| EPS Basic | 95.44% | 96.90% | 82.95% | 69.33% | 89.63% |
| Normalized Basic EPS | 96.80% | 93.31% | 85.96% | 76.43% | -240.25% |
| EPS Diluted | 95.44% | 96.90% | 82.95% | 69.33% | 89.63% |
| Normalized Diluted EPS | 96.80% | 93.31% | 85.96% | 76.43% | -240.25% |
| Average Basic Shares Outstanding | 2,668.66% | 1,169.23% | 1,113.25% | 264.33% | 192.58% |
| Average Diluted Shares Outstanding | 2,668.66% | 1,169.23% | 1,113.25% | 264.33% | 192.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
